阿曲生坦对2型糖尿病合并慢性肾脏病患者疗效的性别差异:SONAR试验的事后分析
SONAR试验事后分析比较阿曲生坦0.75 mg/天与安慰剂在2型糖尿病合并慢性肾脏病患者中的性别差异。女性复合肾脏结局风险显著降低(HR 0.46),男性无显著降低(HR 0.83),交互作用P=0.032;女性心衰住院RR为1.88,男性为1.14,交互作用P=0.217。女性阿曲生坦血浆暴露显著高于男性。
要点
- 女性复合肾脏结局风险显著降低(HR 0.46,95%CI 0.28-0.76),男性无显著降低(HR 0.83,95%CI 0.65-1.05)。
- 女性心衰住院RR为1.88(95%CI 0.98-3.63),男性为1.14(95%CI 0.74-1.76),交互作用P=0.217。
- 女性阿曲生坦血浆暴露几何均值AUC为54.5 ng/ml×h,显著高于男性的42.6 ng/ml×h(P<0.001)。
核心结论
- 阿曲生坦对女性肾脏保护作用大于男性,但也在女性中诱发更多心衰事件。
- 这些数据提示可考虑性别特异性给药方案以优化内皮素受体拮抗剂治疗。
研究设计与样本
- SONAR为双盲、安慰剂对照试验,比较阿曲生坦0.75 mg/天与安慰剂在2型糖尿病合并慢性肾脏病患者中的效果。
- 纳入标准为eGFR 25-75 ml/min per 1.73 m2,尿白蛋白/肌酐比值300-5000 mg/g。
- 共3668例随机参与者,其中女性946例(25.8%)。
- 采用Cox比例风险回归分析比较男女参与者治疗效果,用t检验和线性混合效应模型评估阿曲生坦血浆暴露和eGFR变化差异。
主要发现
- 女性复合肾脏结局风险显著降低(HR 0.46,95%CI 0.28-0.76),男性无显著降低(HR 0.83,95%CI 0.65-1.05),交互作用P=0.032。
- 阿曲生坦较安慰剂减缓eGFR下降的程度女性大于男性(男女治疗效应差异-0.99 ml/min per 1.73 m2,交互作用P=0.020)。
- 心衰住院RR在男性为1.14(95%CI 0.74-1.76),女性为1.88(95%CI 0.98-3.63),交互作用P=0.217。
- 女性阿曲生坦血浆暴露几何均值AUC为54.5 ng/ml×h,显著高于男性的42.6 ng/ml×h(P<0.001)。
关键数值与推荐
- 主要终点为随机化至血清肌酐加倍或肾衰竭(eGFR<15 ml/min per 1.73 m2、慢性透析、肾移植或肾衰竭死亡)首次发生的时间。
- 次要终点为心衰住院。
临床怎么用
- 作者认为可考虑性别特异性给药方案以优化内皮素受体拮抗剂治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: In the Study Of diabetic Nephropathy with AtRasentan (SONAR), the endothelin receptor antagonist (ERA) atrasentan slowed progression of chronic kidney disease (CKD) in individuals with type 2 diabetes. Pre-clinical research suggests sex-based differences in the endothelin system might influence the efficacy and safety of atrasentan. We therefore assessed the effects of atrasentan in men and women participating in SONAR. METHODS: SONAR was a double-blind, placebo-controlled trial that compared atrasentan 0.75 mg/day with placebo in individuals with type 2 diabetes and CKD (eGFR 25-75 ml/min per 1.73 m2, urine albumin/creatinine ratio [UACR] 300-5000 mg/g). The primary endpoint was defined as the time from randomisation to the first occurrence of a doubling in serum creatinine or kidney failure (eGFR <15 ml/min per 1.73 m2, chronic dialysis, kidney transplantation or death from kidney failure). Hospitalisation for heart failure was the secondary endpoint. We performed Cox proportional hazards regression analyses to compare the treatment effect of atrasentan between male and female participants on the risk of the composite kidney outcome as well as hospitalisation for heart failure. Additionally, differences between male and female participants in atrasentan plasma exposure and eGFR change were assessed using, respectively, a t test and linear mixed effect model. RESULTS: Among 3668 randomised participants, 946 (25.8%) were female. Atrasentan significantly reduced the risk of the composite kidney outcome in female participants (HR 0.46 [95% CI 0.28, 0.76]) but not in male participants (HR 0.83 [95% CI 0.65, 1.05]; p value for interaction 0.032). Atrasentan compared with placebo reduced eGFR decline to a greater extent in female than in male participants (treatment effect difference between male vs female participants -0.99 ml/min per 1.73 m2, p value for interaction=0.020). The RR for hospitalisation for heart failure with atrasentan vs placebo was 1.14 (95% CI 0.74, 1.76) in male participants and 1.88 (95% CI 0.98, 3.63) in female participants (p value for interaction=0.217). Female participants also had significantly higher atrasentan plasma exposure than male participants (geometric mean AUC 54.5 vs 42.6 ng/ml×h; p<0.001). CONCLUSIONS/INTERPRETATION: Atrasentan showed greater kidney protection in female than in male participants but also induced more heart failure events in the female participants. These data suggest that sex-specific dosing regimens may be considered to optimise ERA treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT01858532.
引用
- Smeijer JD, de Vries ST, Kohan DE, et al. Sex differences in response to the endothelin receptor antagonist atrasentan in individuals with type 2 diabetes and chronic kidney disease: a post hoc analysis of the SONAR trial. Diabetologia. 2024. PMID: 39661119. doi:10.1007/s00125-024-06326-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。